Yi Tang1,2, Jian-Hui Zhang1, Yao-Bin Zhu3, Shao-Jie Wu1,2, Sen-Lin Cai1,2, Yan-Feng Zhou1,2, Xin Qian1,2, Jie-Wei Luo4,5, Zhu-Ting Fang6,7. 1. Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China. 2. Department of Interventional Radiology, Fujian Provincial Hospital, Fuzhou, 350001, China. 3. Department of Traditional Chinese Medicine, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350001, China. 4. Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China. docluo0421@aliyun.com. 5. Department of Traditional Chinese Medicine, Fujian Provincial Hospital, Fuzhou, 350001, China. docluo0421@aliyun.com. 6. Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China. 470389481@qq.com. 7. Department of Interventional Radiology, Fujian Provincial Hospital, Fuzhou, 350001, China. 470389481@qq.com.
Abstract
PURPOSE: To investigate the safety and effectiveness of superselective prostatic artery embolization (PAE) in patients with benign prostatic hyperplasia (BPH). METHODS: Sixty-five patients diagnosed with BPH in Fujian Provincial Hospital between December 2014 and July 2019 were included. Patients with ineffective drug treatment after 6 months, who refused surgery, or who were unsuitable for surgery were included. We observed postoperative complications, followed up at 1, 3, and 6 months, compared clinical symptoms, and monitored changes in prostate-specific antigen (PSA) and prostatic volume (PV) before and after treatment. RESULTS: Of the 65 patients, 58 (89.23%) successfully received PAE; 44 and 14 bilateral and unilateral embolization, respectively. Clinical efficacy was 94.83% (55/58) after the 6-month follow-up. Postoperative PV, International Prostate Symptom Score, quality of life, maximum flow rate, and post-void residual significantly improved after 6 months (P < 0.05). One month after PAE, the serum total PSA increased by 1.47 (10.84/7.37) times and dropped 3 months later to a level lower than that before surgery (P < 0.05). Six months after PAE, the degree of relief from obstructive symptoms was more apparent than that of irritative symptoms. No serious complications were observed after PAE. CONCLUSION: PAE was safe and effective for the treatment of BPH. The efficacy of bilateral PAE was better than that of unilateral PAE.
PURPOSE: To investigate the safety and effectiveness of superselective prostatic artery embolization (PAE) in patients with benign prostatic hyperplasia (BPH). METHODS: Sixty-five patients diagnosed with BPH in Fujian Provincial Hospital between December 2014 and July 2019 were included. Patients with ineffective drug treatment after 6 months, who refused surgery, or who were unsuitable for surgery were included. We observed postoperative complications, followed up at 1, 3, and 6 months, compared clinical symptoms, and monitored changes in prostate-specific antigen (PSA) and prostatic volume (PV) before and after treatment. RESULTS: Of the 65 patients, 58 (89.23%) successfully received PAE; 44 and 14 bilateral and unilateral embolization, respectively. Clinical efficacy was 94.83% (55/58) after the 6-month follow-up. Postoperative PV, International Prostate Symptom Score, quality of life, maximum flow rate, and post-void residual significantly improved after 6 months (P < 0.05). One month after PAE, the serum total PSA increased by 1.47 (10.84/7.37) times and dropped 3 months later to a level lower than that before surgery (P < 0.05). Six months after PAE, the degree of relief from obstructive symptoms was more apparent than that of irritative symptoms. No serious complications were observed after PAE. CONCLUSION: PAE was safe and effective for the treatment of BPH. The efficacy of bilateral PAE was better than that of unilateral PAE.
Authors: Sandeep Bagla; Cynthia P Martin; Arletta van Breda; Michael J Sheridan; Keith M Sterling; Dimitrios Papadouris; Kenneth S Rholl; John B Smirniotopoulos; Arina van Breda Journal: J Vasc Interv Radiol Date: 2013-10-28 Impact factor: 3.464
Authors: Tiago Bilhim; João Pisco; Hugo Rio Tinto; Lúcia Fernandes; Luís Campos Pinheiro; Marisa Duarte; José A Pereira; António G Oliveira; João O'Neill Journal: Cardiovasc Intervent Radiol Date: 2012-12-12 Impact factor: 2.740
Authors: Valentin Zumstein; Patrick Betschart; Malte W Vetterlein; Luis A Kluth; Lukas Hechelhammer; Livio Mordasini; Daniel S Engeler; Thomas M Kessler; Hans-Peter Schmid; Dominik Abt Journal: Eur Urol Focus Date: 2018-10-03
Authors: Vanessa F Schmidt; Mirjam Schirren; Maurice M Heimer; Philipp M Kazmierczak; Clemens C Cyran; Moritz Wildgruber; Max Seidensticker; Jens Ricke; Olga Solyanik Journal: Diagnostics (Basel) Date: 2022-02-25